Treatment of patients with multiple myeloma than 65–70 years of age and the role of maintenance therapy after transplantation stem cells
Journal Title: OncoReview - Year 2011, Vol 1, Issue 4
Abstract
Treatment of myeloma has changed significantly in the past decade as results of better understanding of disease biology, more effective treatments, and improved supportive care. Autologous stem cell transplantation (SCT) is an effective treatment for myeloma and remains a critical component in its management. Given the potential impact of therapy on stem cell collection, initial treatment decision in myeloma still depend on the patient’s transplant eligibility. The goals of initial therapy remain rapid disease control allowing for reversal of complications, as well as reduction in the risk of early death– all with minimal toxicity. The introduction of new drugs such as thalidomide, bortezomib, and lenalidomide has enabled us to achieve this goal, and combinations of these drugs have also led to unprecedented response depth. In addition, the drugs are newer being explorated as maintenance therapy following SCT. This review summarizes the current approach to the treatment of newly diagnosed myeloma in transplant-eligible patients.
Authors and Affiliations
Artur Jurczyszyn
Keywords
Related Articles
- EP ID EP53121
- DOI -
- Views 209
- Downloads 0
Everolimus-induced interstitial lung disease in patient with metastatic renal cell carcinoma – case report and literature review
We present a case of a 70-year-old man with metastatic renal cell carcinoma treated with second-line everolimus after rapid progression on first-line tyrosine kinase inhibitor, in whom a side effect of the therapy occurr...
Efficacy and safety of liposomal doxorubicin in a patient treated for metastatic breast cancer
Liposomal doxorubicin is a newer form of chemotherapeutic agents that, due to its own special properties, preferably accumulates in cancer tissue. On the other hand, it shows lower affinity to cardiomyocytes and in this...
Results of a multi-centre survey concerning the treatment of hormone-dependent breast cancer in Poland in 2009–2013
In order to present a reliable picture of hormone-dependent breast cancer treatment in Poland, an on-line survey has been conducted in 19 oncology centres. As a result, data on the treatment of 486 patients have been obt...
Terapia ewerolimusem u pacjenta z zaawansowanym nowotworem neuroendokrynnym trzustki – opis przypadku
Coraz częstsze występowanie nowotworów neuroendokrynnych przewodu pokarmowego jest spowodowane nie tylko rzeczywistym wzrostem zachorowalności, ale także postępem w zakresie ich diagnostyki. Właściwe rozpoznanie oraz oce...
Original vs generic drugs in treatment of chronic myeloid leukaemia
The beginning of the twenty-first century saw a breakthrough in haematology, oncology and general medicine driven by the introduction of imatinib (Glivec) to the treatment of chronic myeloid leukaemia. For the first time...